Drug Trial Radar · NCT07410611
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Feb 28, 2030
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- Hebei Medical University Fourth HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Befotertinib is a third-generation EGFR-TKI independently developed in China. In first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, it has demonstrated a median progression-free survival (PFS) of 22.1 months, representing the longest reported PFS data among currently available third-generation EGFR-TKIs. Building on the clinical advantages of this agent and addressing the unmet therapeutic needs in oligometastatic NSCLC, this study aims to conduct a prospective exploration by dynamically monitoring circulating tumor DNA (ctDNA) to guide the application of befotertinib combined with radiotherapy in patients with EGFR mutation-positive oligometastatic NSCLC.
Conditions
- Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Interventions
BefotertinibDrug
Subjects will receive treatment with Befotertinib. Peripheral blood will be collected 8 weeks (±7 days) later for ctDNA testing. Those who test positive for ctDNA will undergo treatment intensification with Befotertinib combined with radiotherapy, while those who test negative will continue with Befotertinib monotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: From date of initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 mont
- PFSTime frame: From date of initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 22 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.